35 results about "Gentisic acid" patented technology

Vitamin E conjugates, methods for their preparation, and compositions that include the conjugates. The vitamin E conjugates include a tocopherol moiety covalently coupled through a linker moiety to either a pyroglutamate moiety, a pyrrolidinone moiety, or a gentisic acid moiety.

The invention relates to a method for fast and high-efficient determination of 13 phenolic acids in grape wine, belonging to the technical field of analysis of flavor substances in the grape wine. According to the method disclosed by the invention, ultra-performance liquid chromatography is utilized for performing qualitative and quantitative analysis on phenolic acid substances in the grape wine, and the method specifically comprises the following steps: selecting a BEHC18 chromatographic column, taking 2% acetic acid water and methanol as a mobile phase, setting the flow rate at 0.3mL/min, performing ultraviolet detection on wavelength to get the result that the wavelength of gentisic acid is 320nm and the wavelength of the remainder is 280nm, setting the column temperature at 50 DEG C, setting the sample injection quantity at 1 mu L, and quantifying by a peak area external reference method; and by adopting the method, the detection and the analysis can be simultaneously performed on the 13 phenolic acids in the grape wine within 10min. According to the method disclosed by the invention, any sample pretreatment is not required, and the loss caused by the pretreatment can be avoided; and compared with traditional HPLC (high-performance liquid chromatography), by adopting the method disclosed by the invention, more phenolic acid type compounds can be simultaneously detected, the separation effect is good, the analysis process is greatly shortened, convenient and easy to operate, the detection efficiency is greatly improved and the cost of the mobile phase is saved. The method disclosed by the invention has important significance for further system research of the flavor substances in the grape wine and improvement of the quality of the grape wine.

The present invention relates to stabilised <99m>Tc radiopharmaceutical compositions, which include both a radioprotectant and one or more antimicrobial preservative(s), and hence have an extended lifetime of use. The radioprotectant is ascorbic acid, para-aminobenzoic acid, gentisic acid or a salt thereof with a biocompatible cation, and the antimicrobial preservative is one or more compound from the paraben series of preservatives. The invention is particularly useful for cationic, lipophilic <99m>Tc heart imaging agents such as Myoview(TM).

The invention discloses a marine heavy-duty anti-corrosion coating and a preparation method thereof. The coating comprises the following components in parts by weight: 5-15 parts of mica powder, 10-15 parts of B-N ligand polyaniline/montmorillonite composite conductive material, 8-15 parts of talcum powder, 10-15 parts of quartz powder, 30-40 parts of matrix resin, 0-3 parts of pigment, 0.5-1.0 part of defoamer, 0.5-1.0 part of dispersant, 0.5-1.0 part of coalescing agents and 30-40 parts of solvent, wherein the B-N ligand polyaniline/montmorillonite composite conductive material is synthesized by montmorillonite activated and modified by a surfactant, an organic boronic acid, an aniline monomer and double phenolic hydroxyl derivatives; the organic boronic acid is one of a 2-methyl phenyl boronic acid, a 3-methyl phenyl boronic acid, a 4-methyl phenyl boronic acid, a 3,5-dimethylphenylboronic acid, a phenylboronic acid and 4-methoxy benzene boron; the double phenolic hydroxyl derivatives are one of 3,4-gentisic acid methyl ester, 3,4-dihydroxy benzaldehyde and 3,4-dihydroxy benzoic acid ethyl ester. The coating is excellent in corrosion resistance.

The invention belongs to the field of application environment microorganism and agriculture, and discloses gentisic acid dioxygenase as well as a coding gene and application thereof. A gentisic acid dioxygenase gene dsmD has a nucleotide sequence shown in SEQ ID NO.1, the total length of the dsmD is 1053bp, 350 amino acids are coded, and the amino acid sequence of the dsmD is shown in SEQ ID NO.2.The gentisic acid dioxygenase gene is the first gene disclosed to degrade 3-chlorogentic acid, an intermediate metabolite of dicamba, and a protein coded by the gene is capable of carrying out ring-opening degradation on gentisic acid and 3-chlorogentic acid. The gentisic acid dioxygenase provided by the invention can degrade gentisic acid and 3-chlorogentisic acid of 100mg/l within 30min. Therefore, the gentisic acid dioxygenase gene dsmD has a great potential in constructing transgenic crops for degrading dicamba, and the gentisic acid dioxygenase protein DsmD has a good application prospect in degrading dicamba and benzene ring substances.

The invention relates to the field of pollutant controlling, and specifically relates to a vegetable tannin algae inhibitor and a method for inhibiting the overgrowth of algae in eutrophicated fresh water areas. The vegetable tannin algae inhibitor provided by the invention comprises one or more components selected from gentisic acid, ellagic acid, and tannic acid. All the components of the algaeinhibitor can be obtained through artificial synthesizing, and are cheap in price. The preparation method of the complex agent is simple, and has a strong operability. With the algae inhibitor, secondary pollution to the environment is not caused, water areas can be prevented from water bloom, and the stability of aquatic ecosystems can be maintained. With the complex algae inhibitor provided by the invention, over dose of single component can be effectively avoided, such that the damage to the aquatic ecosystems can be prevented, and various degrees of drug resistances gradually generated inalgae caused by long-term and repeated usage of single algae inhibitor can be effectively overcome or retarded. Also, with the algae inhibitor, algae inhibiting capacity and broad spectrum property of the algae inhibitor can be effectively improved.

The invention discloses a nicotine-gentisate complex crystal. A molecular formula of the nicotine-gentisate complex crystal is C7H6O4 C10H16N2; the nicotine-gentisate complex crystal belongs to monoclinic crystal systems and is provided with space groups P21, unit cell parameters alpha and gamma are 90.00 degrees, and a unit cell parameter beta is equal to 112.40 degrees. The invention further discloses a method for preparing the nicotine-gentisate complex crystal and a tobacco product with the nicotine-gentisate complex crystal. The method includes a, placing gentisic acid in a conical flask,adding solvents into the conical flask, further adding distilled water into the conical flask and stirring the gentisic acid, the solvents and the distilled water until the gentisic acid, the solvents and the distilled water are uniformly mixed with one another; b, carrying out light-resistant treatment on the conical flask obtained at the step a, dropwise adding nicotine under a stirring condition and controlling the reaction temperature and the pH (potential of hydrogen); c, filtering solution obtained after reaction is carried out at the step b, allowing the solution to stand still at normal-temperature light-resistant locations and drying the solution to obtain brown viscous liquid; d, placing the brown viscous liquid obtained at the step c at normal-temperature light-resistant locations and allowing crystals to grow so as to obtain brown transparent needle-shaped solid. The tobacco product can be a gum-based chewing tobacco, a mouth tobacco in bags, electronic cigarette liquid ora heating incombustible cigarette.

The invention discloses application of a 2-acetylamino gentisic acid compound with protein tyrosine phosphatase 1B inhibitory activity to preparing an insulin sensitizer. The 2-acetylamino gentisic acid can be used for preparing drugs for treating diabetes, obesity and complications thereof caused by insulin resistance and is obtained by fermenting and separating deep-sea streptomyces sp. 220225.

The invention relates to Klebsiella pneumoniae M5a1 gentisic acid 1, 2-bioxygenase gene engineered bacteria construction and uses thereof. Gentisic acid 1, 2-bioxygenase gene engineered bacteria construction method includes: LB medium ,engineered bacteria proliferation and following steps. (1)gentisic acid 1, 2-bioxygenase gene cloning and high expression (2) extraction of gentisic acid 1, 2-bioxygenase preparation of cisethylene dicarboxylic mono-acyl keto acetic acid using gentisic acid 1, 2-bioxygenase gene engineered bacteria. The invention is convenient to operate. Cisethylene dicarboxylic mono-acyl keto acetic acid product purity is high, being suitable for scale production and uses.

The invention discloses high-purity gentisic acid, the purity of the high-purity gentisic acid is greater than or equal to 99.50%, the high-purity gentisic acid comprises gentisic acid, salicylic acid and an impurity A, and the structural formula of the impurity A is shown in the specification. The invention also discloses an application of the high-purity gentisic acid in preparation of an antiviral agent, an antibacterial agent, an analgesic or an antioxidant excipient. The high-purity gentisic acid is prepared through a specific preparation method, the yield of the high-purity gentisic acid can reach 18-22%, and the high-purity gentisic acid is suitable for large-scale industrial production.

The invention discloses an anti-osteoporosis drug, relates to the technical field of research and development of anti-osteoporosis drugs, and particularly relates to an anti-osteoporosis drug. The anti-osteoporosis drug comprises a prepared rehmannia root water extract and main monomer components thereof, namely echinacoside, rehmannioside, verbascoside, scorch-fried rehmannioside, isophenoside, verbascoside, catalpol, rehmannioside A, rehmannioside B, rehmannioside D, Rehmaionoside A, Rehmaionoside B, Rehmaionoside C, rehmanniin A, rehmanniin B, rehmanniin D, rehmanniin C, leonuride, rehmannioside D, geniposide, gentisic acid, apigenin, oleanolic acid, polysaccharide and reducing sugar, and derivatives of the components. In the anti-osteoporosis drug, the prepared rehmannia root water extract can prolong the reaction time of photothermal pain of ovarian estrogen deprived rats, can increase the mechanical touch-induced pain threshold of the ovarian estrogen deprived rats, and can reduce formalin inflammatory pain of the ovarian estrogen deprived rats.

The invention provides a compound I liquid composition, a preparation method and application thereof, and the compound I liquid composition is selected from one or more than two of vitamin C, vitamin C sodium and gentisic acid. By optimizing process parameters and the process flow, the method can be suitable for mass production, and the obtained product is high in radiochemical purity, high in activity concentration, good in product stability and high and stable in yield or yield.

The invention relates to novel gentisic acid derivatives (2-hydroxy-5-alkyl (H) oxo benzoates), which have a structural formula shown in the specification, wherein R1 is any one of hydrogen, methyl, ethyl, benzyl and p-nitrobenzyl; and R2 is hydrogen or methyl. The invention also discloses a new application of the novel gentisic acid derivatives (2-hydroxy-5-alkyl (H) oxo benzoates) in the beauty and whitening field. The novel gentisic acid derivatives (2-hydroxy-5-alkyl (H) oxo benzoates) have the advantages of low toxicity, high stability, better pharmacological activity and excellent beauty and whitening effect.

The invention belongs to the field of health-care products, and particularly relates to a pharmaceutical composition containing gentisic acid and application of the pharmaceutical composition. The composition comprises the effective components of the gentisic acid and cabernet sauvignon pomace extract, wherein the mass percentage of the effective components is 0.3-1.2 wt%, and the balance is a pharmaceutically acceptable carrier; and in the effective components, the mass percent ratio of the gentisic acid to the cabernet sauvignon pomace extract is 1: 5. The application of the pharmaceutical composition containing the gentisic acid and the cabernet sauvignon pomace extract is used for treating obesity and related diseases. According to the obtained pharmaceutical composition, the effectivecomponents of the gentisic acid and the cabernet sauvignon pomace extract can effectively inhibit body obesity caused by high-fat and high-sugar diet and improve glucose tolerance and insulin resistance of the body, so that a new treatment way is opened up for treatment of the obesity and related diseases.

The present invention relates to salts of a pyrrolopyrimidinone derivative having superior PDE-5 inhibition activity and a process for preparing the same. More particularly, the present invention relates to a crystalline acid addition salt prepared by reacting a pyrrolopyrimidinone derivative with an acid selected from gentisic acid, maleic acid, citric acid, fumaric acid and tartaric acid. With no hygroscopic property and superior long-term storage stability, photostability and thermal stability, the salts of the pyrrolopyrimidinone derivative are appropriate to be prepared into medications and, with superior PDE-5 inhibition activity, are useful for the treatment and prevention of erectile dysfunction, pulmonary arterial hypertension, chronic obstructive pulmonary disease, benign prostatic hypertrophy and lower urinary tract diseases.